Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecutive patients, including 468 patients with assessab...

Full description

Bibliographic Details
Main Authors: Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Diagnostics
Subjects:
breast cancer
neoadjuvant therapy
pathological complete response
residual cancer burden
biomarkers
KI-67
Online Access:https://www.mdpi.com/2075-4418/12/7/1740

Internet

https://www.mdpi.com/2075-4418/12/7/1740

Similar Items